Shares of ICAD opened at $4.77 on Friday. The company has a current ratio of 1.60, a quick ratio of 1.48 and a debt-to-equity ratio of 1.63. The firm has a market cap of $84.63 million, a price-to-earnings ratio of -12.55 and a beta of 1.36. iCAD has a 12 month low of $2.42 and a 12 month high of $6.10.
iCAD (NASDAQ:ICAD) last issued its quarterly earnings results on Monday, March 18th. The technology company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.01. The business had revenue of $6.95 million for the quarter, compared to analysts’ expectations of $6.55 million. iCAD had a negative net margin of 35.19% and a negative return on equity of 65.03%. As a group, sell-side analysts predict that iCAD will post -0.31 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of ICAD. IHT Wealth Management LLC bought a new stake in iCAD during the fourth quarter valued at $48,000. Columbia Pacific Advisors LLC bought a new position in shares of iCAD during the 4th quarter worth about $74,000. FNY Investment Advisers LLC bought a new position in shares of iCAD during the 4th quarter worth about $75,000. Advisor Group Inc. boosted its position in shares of iCAD by 96,087.0% during the 4th quarter. Advisor Group Inc. now owns 22,123 shares of the technology company’s stock worth $82,000 after purchasing an additional 22,100 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in shares of iCAD by 33.5% during the 4th quarter. Deutsche Bank AG now owns 35,923 shares of the technology company’s stock worth $132,000 after purchasing an additional 9,023 shares in the last quarter. 17.02% of the stock is currently owned by institutional investors and hedge funds.
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Further Reading: Special Dividends
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.